WallStSmart

Live Ventures Inc (LIVE)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

West Pharmaceutical Services Inc generates 629% more annual revenue ($3.22B vs $441.98M). WST leads profitability with a 16.9% profit margin vs 5.0%. LIVE trades at a lower P/E of 2.6x. WST earns a higher WallStSmart Score of 67/100 (B-).

LIVE

Hold

44

out of 100

Grade: D

Growth: 4.0Profit: 5.5Value: 8.3Quality: 6.0
Piotroski: 5/9Altman Z: 2.02

WST

Strong Buy

67

out of 100

Grade: B-

Growth: 7.3Profit: 8.0Value: 2.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

LIVEUndervalued (+89.0%)

Margin of Safety

+89.0%

Fair Value

$177.00

Current Price

$13.25

$163.75 discount

UndervaluedFair: $177.00Overvalued
WSTSignificantly Overvalued (-32.4%)

Margin of Safety

-32.4%

Fair Value

$185.95

Current Price

$325.92

$139.97 premium

UndervaluedFair: $185.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LIVE3 strengths · Avg: 9.7/10
P/E RatioValuation
2.6x10/10

Attractively priced relative to earnings

Price/BookValuation
0.4x10/10

Reasonable price relative to book value

Return on EquityProfitability
26.3%9/10

Every $100 of equity generates 26 in profit

WST4 strengths · Avg: 9.0/10
EPS GrowthGrowth
56.1%10/10

Earnings expanding 56.1% YoY

Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.7%8/10

Strong operational efficiency at 21.7%

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

LIVE4 concerns · Avg: 3.0/10
Market CapQuality
$37.66M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
5.0%3/10

5.0% margin — thin

Operating MarginProfitability
3.2%3/10

Operating margin of 3.2%

Debt/EquityHealth
1.213/10

Elevated debt levels

WST2 concerns · Avg: 2.0/10
PEG RatioValuation
2.892/10

Expensive relative to growth rate

P/E RatioValuation
41.8x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : LIVE

The strongest argument for LIVE centers on P/E Ratio, Price/Book, Return on Equity.

Bull Case : WST

The strongest argument for WST centers on EPS Growth, Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : LIVE

The primary concerns for LIVE are Market Cap, Profit Margin, Operating Margin.

Bear Case : WST

The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 41.8x leaves little room for execution misses.

Key Dynamics to Monitor

LIVE profiles as a value stock while WST is a growth play — different risk/reward profiles.

WST carries more volatility with a beta of 1.17 — expect wider price swings.

WST is growing revenue faster at 21.0% — sustainability is the question.

WST generates stronger free cash flow (47M), providing more financial flexibility.

Bottom Line

WST scores higher overall (67/100 vs 44/100), backed by strong 16.9% margins and 21.0% revenue growth. LIVE offers better value entry with a 89.0% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Live Ventures Inc

CONSUMER CYCLICAL · HOME IMPROVEMENT RETAIL · USA

Live Ventures Incorporated is engaged in flooring manufacturing, steel fabrication and retail businesses in the United States. The company is headquartered in Las Vegas, Nevada.

Visit Website →

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?